Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Isofol in connection with capital procurement
Mandate

Vinge advises Isofol in connection with capital procurement

June 14, 2021 Capital Markets and Public M&A

Vinge has advised Isofol Medical AB (publ), Nasdaq First North Premier Growth Market, in connection with a fully guaranteed rights issue and exercised over-allotment option which together add SEK 500 million to Isofol before transaction costs.

Vinge’s team primarily consisted of Anders Strid, Edin Agic, Jenny Sandlund and Beatrice Randow.

Related

Vinge advises Borgo in connection with its inaugural issuance of primary capital instruments (AT1)

 Vinge has advised Borgo AB (publ) in connection with its successful issuance of primary capital instruments (so called “AT1 bonds”) in the amount of SEK 350 million with a floating rate coupon of 3-month STIBOR + 390 basis points.
January 29, 2026

Vinge advises J Bil in conjunction with the acquisition of Appelskog Bil AB

 Vinge has advised the buyer J Bil AB in conjunction with the acquisition of all shares in Appelskog Bil AB.
January 29, 2026

Vinge has advised United Lithium Corp. in connection with the acquisition of Swedish Minerals AB

 United Lithium is an exploration & development company focused on the global demand for lithium, uranium and rare earth elements.
January 29, 2026